undamentalytics Newsletter
Sign in

Inspiremd, Inc. income statement

In fiscal 2025, Inspiremd, Inc. reported revenue of $9.0m, up 28.1% on the year before, operating income of −$49.6m (a -552.6% margin) and net income of −$48.8m, or −$0.76 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Jun 20122013Jun 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue3565532234424567911
Cost of revenue233322322332444669
Gross profit123331−001110112232
Research and development112449411232588141516
Selling and marketing11224731222234461720
General and administrative131214996555567811152119
Operating income−3−3−14−18−15−24−14−8−8−8−10−10−15−19−21−34−50−54
Interest expense001141110—————————
Income before tax−3−3−15−18−29−25−16−8−8−7−10−11−15−18−20−32−49—
Income tax000000000—0000000—
Net income−3−3−15−18−29−25−16−8−8−7−10−11−15−18−20−32−49−52
Diluted EPS−$0.00−$0.00−$30.00−$8.67−$11.58−$5.91−$3.72−$13.85−$2.33−$1.11−$0.32−$0.46−$0.68−$0.78−$0.82−$0.76−$0.76−$0.65
Diluted shares (average)———2,005m3m4m4m—6m7m31m23m22m24m24m42m64m81m
EBITDA−3−3−14−17−15−23−14−8−8−7−10−10−15169211246426423

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: NSPR vs WOKHSDT vs NSPRNMTC vs NSPRNNOX vs NSPR

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Inspiremd, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Inspiremd, Inc.